ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.
Yuhan, Elevar, Hengrui and Astellas—Fierce Pharma Asia fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) A new cancer medicine developed by AstraZeneca Plc and Daiichi Sankyo Co. seemed to fall short of investors’ expectations in partial results released early after a data leak at a medical conference. Most Read from BloombergBiden Vows Aid for Gaza, Backs Israel Over Hospital BlastHospital Blast Kills Hundreds as Israel, Hamas Trade BlameStocks Drop, Oil Climbs on Renewed Mideast Risks: Markets WrapUPenn Donors Pile Pressure on School as David Magerman Pulls SupportIsrael Latest: Bi
Takeda Pharmaceutical drug Exkivity failed the confirmatory study required of its 2021 accelerated approval. Our recap of other recent regulatory developments includes a partial clinical hold on a cancer drug, a Covid-19 vaccine authorization, and several drug approvals in the U.S. and beyond.